verdiperstat
Small moleculeexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
3
Phase 4
0
Earliest trial started Jul 30, 2019 (NCT03952806)
Timeline
Indications
Mechanism of action
- MyeloperoxidaseINHIBITOR
Myeloperoxidase inhibitor
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)OCCn1c(=S)[nH]c(=O)c2[nH]ccc21- Mol. weight
- 253.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297594 ↗
Also known as
- verdiperstat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05184569 | Phase 1 | Apr 14, 2022 | Alzheimer's Association, National Institute on Aging (NIA), National Institutes of Health (NIH), University of California, San Francisco |
| NCT04616456 | Early Phase 1 (Phase 1) | Dec 31, 2020 | Biohaven Pharmaceuticals Inc., Harvard University |
| NCT04436510 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2020 | Biohaven Pharmaceuticals Inc., Harvard University |
| NCT04297683 | Phase 2/Phase 3 (Phase 3) | May 31, 2020 | Harvard University |
| NCT03952806 | Phase 3 | Jul 30, 2019 | Biohaven Pharmaceuticals Inc. |
| NCT05086094 | N/A | — | Biohaven Pharmaceuticals Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biohaven Pharmaceuticals Inc. | For profit | 4 | 2 | 3 | 2019 |
| Harvard University | Academic/Hospital | 3 | 3 | 2 | 2020 |
| Alzheimer's Association | Academic/Hospital | 1 | 0 | 1 | 2022 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2022 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2022 |
6 organizations
Page 1 / 1